ADAM17 (where ADAM is 'a disintegrin and metalloproteinase') can rapidly modulate cell-surface signalling events by the proteolytic release of soluble forms of proligands for cellular receptors. Many regulatory pathways affect the ADAM17 sheddase activity, but the mechanisms for the activation are still not clear. We have utilized a cell-based ADAM17 assay to show that thiol isomerases, specifically PDI (protein disulfide isomerase), could be responsible for maintaining ADAM17 in an inactive form. Down-regulation of thiol isomerases, by changes in the redox environment (for instance as elicited by phorbol ester modulation of mitochondrial reactive oxygen species) markedly enhanced ADAM17 activation. On the basis of ELISA binding studies with novel fragment antibodies against ADAM17 we propose that isomerization of the disulfide bonds in ADAM17, and the subsequent conformational changes, form the basis for the modulation of ADAM17 activity. The shuffling of disulfide bond patterns in ADAMs has been suggested by a number of recent adamalysin crystal structures, with distinct disulfide bond patterns altering the relative orientations of the domains. Such a mechanism is rapid and reversible, and the role of thiol isomerases should be investigated further as a potential factor in the redox regulation of ADAM17.
INTRODUCTION
The disintegrin metalloproteinases of the ADAM family (where ADAM is 'a disintegrin and metalloproteinase') are associated with the process of proteolytic 'shedding' of membraneassociated proteins and hence the rapid modulation of key cell signalling pathways in the tumour microenvironment. ADAM17 {also known as TACE [TNFα (tumour necrosis factor α)-converting enzyme]} represents the archetypal signalling switch, with a plethora of apparent cell membrane substrates, constituting part of the link between the cell and its environment. ADAM17 is thought to effect the proteolytic shedding not only of TNFα, but also of a number of the EGFR [EGF (epidermal growth factor) receptor] ligands, cell-adhesion molecules, such as Lselectin, and many growth factor receptors [1, 2] . One of the most important and remarkable features of ADAM17 function is the speed with which it can be activated at the cell surface, allowing the cell to rapidly modulate its signalling status [1] . A major outstanding question is the mechanisms by which this change may be effected. ADAM17 activity has been shown to be regulated by phorbol esters [2, 3] , kinases and phosphatases, as well as G-protein-coupled receptor signalling (reviewed in [4] ). ROS (reactive oxygen species) have frequently been identified as mediators of ADAM17 activation in these signalling pathways [5, 6] and may be involved in ADAM17 responses to many stressrelated stimuli [7] . The function of accessory proteins, including ERAP1 (endoplasmic reticulum aminopeptidase 1) [8] , nardilysin [9] and CD9 [10] has also been invoked in the modulation of specific ADAM17 shedding activities, although none of the mechanisms of action are clear. The localization of both enzyme and substrate relative to lipid-raft structures in cell membranes has been proposed as a level of regulation [11] . The availability of ADAM17 substrates is likely to be another component of the regulatory mechanism and it is documented that ROS stimulate the trafficking of pro-HB-EGF (heparin-binding EGF) to a detergent-resistant membrane compartment where proteolytic processing and release of the soluble mature form occurs [12] .
Many of the substrates of ADAM17 are complex disulfidebonded proteins and there have been studies showing that the thiol status of these proteins can modulate their propensity for proteolytic shedding. L-selectin is an example where thioloxidizing or thiol-blocking reagents are stimulatory and thiol-reducing agents are inhibitory to shedding by ADAM17 [13] . The involvement of cell-surface localized PDI (protein disulfide isomerase) as a modulator of the cleavable form of Lselectin was proposed based on the ability of the PDI inhibitor bacitracin and an inhibitory antibody against PDI to markedly potentiate shedding [14] . Studies have shown that the thiolreactive reagent APMA (4-aminophenylmercuric acetate) can stimulate proteolytic shedding from cells, and effects on both the substrate and the protease have been proposed [14, 15] . Redox mechanisms for the regulation of extracellular events are of some importance and the presence of redox-active proteins has been described for different cell types [16] [17] [18] . PDI, which has two active sites containing vicinal thiols that are in equilibrium with disulfide bonds, can catalyse thiol-disulfide interchanges, leading
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to the net formation or the net reduction of disulfide bonds, or simply their rearrangement. Although largely an endoplasmicreticulum-based protein, an active form of PDI appears at the cell surface and appears to be a dithiol form that catalyses the reduction or isomerization of disulfide-bonded proteins. PDI was shown to expose a cryptic cell binding site in TSP1 (thrombospondin 1) [19] . Another thiol isomerase, ERp5 (endoplasmic reticulum protein 5) has been shown to regulate adhesion of platelets, probably via the activation of integrins [20] . The exchange of thiols on CD4 by the thiol isomerase thioredoxin is required for the entry of HIV type 1 into cells [21] . Thioredoxin and PDI are regenerated from their oxidized forms by the enzyme thioredoxin reductase, which can also be secreted from cells [22] . All of these proteins have copies of the thioredoxin motif CxxC and can, in principle, act as thiol oxidants, reductants or as disulfide isomerases for vicinal dithiols in substrate proteins. Interestingly, ADAM17, like some integrins [23] , has two thioredoxin motifs in the disintegrin-cysteine-rich domain. The Walcheck laboratory demonstrated that these motifs are critical for L-selectin cleavage activity of ADAM17 and suggested that ADAM17 might be regulated by extracellular redox conditions, either via PDI or other endogenous thiol isomerase activities [24] . In the present study we have shown that PDI has the potential to regulate cellular ADAM17 activity by isomerization of its disulfide bonds. We developed novel conformation-specific antibodies and used them to show that treatment of recombinant ADAM17 with PDI causes a change in the accessibility of antibody-binding motifs on ADAM17, i.e. a structural change in the protease and a loss of proteolytic activity.
EXPERIMENTAL

Materials
Unless stated otherwise, chemicals were purchased from Sigma-Aldrich, including purified bovine PDI. ] with a C-terminal His 6 tag was prepared as described previously [25] . MitoQ was a gift from Professor M. Murphy (MRC Mitochondrial Biology Unit, Cambridge, U.K.) [26] . GST (glutathione transferase)-tagged pro-TNFα (GST-pro-TNFα), was prepared as described previously [27] . Protein models were visualized in PyMOL.
Production and assay of recombinant ADAM17
The recombinant ADAM17 ectodomain (TACE651; Arg 215 -Arg 651 ) was expressed from baculovirus (a gift from Dr J. D. Becherer, GlaxoSmithKline Research Triangle Park, NC, U.S.A.) and purified according to the method of Milla et al. [28] , with minor modifications. The 60 kDa protein produced represents the mature ectodomain as proprotein convertase processing of the propeptide occurs during sf9 cell expression. The mature catalytic domain of ADAM17 (TACE477GH-His 6 ; Arg 215 -Val 477 ) was also prepared using the baculovirus system and was a gift from Dr M. Taylor and Dr P. Newham (AstraZeneca, Macclesfield, U.K.). In vitro assays of recombinant ADAM17 activity were carried out using the quenched fluorescent peptide (7-methoxycoumarin-4-yl)-acetyl-Lys-Pro-Leu-Gly-ProLeu-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg-NH 2 (Calbiochem), as described below.
Cell culture
HeLa and MCF7 cells (Cancer Research U.K.; passages were cultured at 37
• C in DMEM (Dulbecco's Modified Eagle Medium, Gibco) with 10 % (v/v) foetal bovine serum and 2 mM L-glutamine, and were used after 24-48 h at 80 % confluence.
HB-EGF and AP (alkaline phosphatase) shedding assays
A cDNA for pro-HB-EGF fused to an AP reporter, HB-EGF-AP, was cloned into the pRc/CMV plasmid (Invitrogen), which confers neomycin resistance, and was stably transfected into HeLa cells using FuGENE ® 6 (Roche). MCF7 cells overexpressing HB-EGF were a gift from Dr Rosalyn Adam (Boston Children's Hospital, Boston, MA, U.S.A.). Stably transfected HeLa and MCF7 cells were selected with 800 and 600 ng/ml G418 respectively. Cellular expression of the fusion proteins was verified by Western blotting using an anti-HB-EGF and an anti-AP antibody. Unless otherwise stated 2 × 10 4 cells were seeded per well in a 48-well plate for each experiment. After 48 h, cells were washed twice with serum-free medium and treated with the various agents in serum-free medium at the concentrations and for the time periods indicated. After treatment, medium was collected, spun down at 25 000 g for 5 min before 40 μl of medium was removed from each sample and added to 100 μl of AP substrate (5 mM p-nitrophenyl phosphate disodium and 1 mM diethanolamine, pH 9.5) and 50 μM MgCl 2 , 0.15 M NaCl, 0.5 M Tris/OH and 5 mM EDTA, pH 9.7. After an overnight incubation, AP activity was measured with a Tecan Spectrafluor Plus microplate reader at 405 nm.
Studies with PDI
Bacitracin, a general thiol isomerase inhibitor, and the PDI inhibitory antibody RL90 were used to inhibit PDI. Bacitracin was purified to remove the bulk of the contaminating proteases and finally treated with PMSF [29] . Loss of protease activity was confirmed using a myelin-basic-protein cleavage assay. The PDI inhibitory activity was confirmed in vitro using purified bovine PDI in the insulin reduction assay [30] .
Cells were pre-incubated at 4
• C with 3 mM bacitracin for 5 min, or the inhibitory PDI antibody RL90 (10 μg/ml) for 30 min, followed by stimulation with PMA (100 ng/ml) for 30 min. The medium was collected, spun down (25 000 g for 5 min) and assayed for AP. Purified PDI was incubated in the presence of 10-fold molar excess DTT (dithiothreitol) for 15 min at room temperature (∼21
• C). Excess DTT was removed by passing the reduced PDI through two desalting columns (Pierce). PDI was then added to cells at various concentrations, followed by PMA stimulation (100 ng/ml) for 30 min. The medium was collected, spun down (25 000 g for 5 min) and assayed for AP activity.
Studies with ROS inhibitors
NAC (N-acetylcysteine), which increases intracellular pools of free radical scavengers, and MitoQ, a mitochondrial ROS inhibitor, were used to investigate the effect of (mitochondrial) ROS on ADAM17 activity. Cells were pre-incubated with various concentrations of NAC or MitoQ for 15 min, followed by stimulation with 100 ng/ml PMA for 30 min at 37
• C. The medium was collected, spun down (25 000 g for 5 min) and assayed for AP activity.
SDS/PAGE and Western blotting
Cells were lysed in ice-cold buffer [50 mM Tris/HCl, pH 7.4, containing 1 % (v/v) Triton X-100 and 500 mM NaCl] with protease inhibitor mix for 15 min at 4
• C. Protein concentration was determined with the BCA protein quantification kit (Pierce). Protein samples, mixed with Laemmli sample buffer, were separated by SDS/PAGE (6-12 % gels). Protein was transferred on to Hybond-C nitrocellulose membranes and blocked with PBS or TBS (Tris-buffered saline) with 5 % (w/v) low-fat milk powder for 2 h at room temperature before overnight incubation with the appropriate primary antibody at 4
• C. Blots were washed in PBS or TBS, with 0.1 % Tween 20, and incubated with HRP (horseradish peroxidase)-conjugated secondary antibody (1:5000 dilution) for 1 h at room temperature, before being washed again, developed with enhanced chemiluminescence and exposed to Hyperfilm (GE Healthcare). Films were quantified by densitometry.
Biotinylation experiments
Subconfluent HeLa cells (5 × 10 5 ) were used for each condition. After cells were incubated with the reagents for the time indicated, cells were washed and surface-biotinylated for 45 min at 4
• C with EZ-Link sulfo-NHS (N-hydroxysuccinimido)-biotin (Thermo Scientific) in PBS to label amine groups or with 100 μM MPB [3-(N-maleimido-propionyl) biocytin; Pierce] in Hepesbuffered saline (21 mM Hepes, pH 7.05, 0.137 M NaCl, 5 mM KCl, 0.76 mM Na 2 HPO 4 · H 2 O and 5.56 mM dextrose) to label thiol groups. EZ-Link sulfo-NHS-biotin labelling was quenched with 50 mM Tris/HCl (pH 7.5) for 10 min at 4
• C. MPB labelling was quenched with 200 μM reduced GSH in Hepes-buffered saline for 20 min at 4
• C. Excess GSH was quenched with 400 μM iodoacetamide for 5 min at 4
• C. Subsequently, cells were washed and lysed with lysis buffer [50 mM Tris/HCl, pH 7.4, containing 1 % (v/v) Triton X-100, 150 mM NaCl and protease inhibitors]. Lysates were pre-cleared with Protein G-Sepharose beads for 30 min and incubated with streptavidin magnetic beads (Magnasphere; Promega) overnight at 4
• C. To release complex from beads, beads were washed and boiled in 1 % (w/v) SDS in Laemmli buffer for 2 min. Samples were subjected to SDS/PAGE and Western blotting (BioRad Systems) before being probed with antibodies against ADAM17, PDI (RL77) and HB-EGF.
Co-immunoprecipitation studies
Subconfluent HeLa cells (1 × 10 6 ) were used for each condition. After exposure to 100 ng/ml PMA for 30 min, cells were washed and surface aminobiotinylated with EZ-Link sulfo-NHS-biotin as described above. To trap mixed disulfide intermediate complexes between PDI and ADAM17, cells were incubated in 10 % (w/v) trichloroacetic acid for 30 min at 4
• C, before the pH was adjusted to 7.0 with Tris/OH (pH 9.5) [31] . Subsequently, cells were washed and lysed with Triton X-100 lysis buffer [50 mM Tris/HCl, pH 7.4, containing 1 % (v/v) Triton X-100, 150 mM NaCl, protease inhibitors and N-ethylmaleimide]. Lysates were passed through a 26G needle before being pre-cleared with Protein G-Sepharose beads and immunoprecipitation was performed with the polyclonal IgY chicken anti-ADAM17 antibody. To release complexes from the beads, samples were washed, boiled in PBS with 1 % (w/v) SDS and then diluted 10-fold with buffer (50 mM Tris/HCl, pH 7.4, containing 150 mM NaCl and protease inhibitor mix). Secondary immunoprecipitation was performed with streptavidin magnetic beads. Samples were then subjected to SDS/PAGE and Western blotting. Finally, membranes were probed with antibodies against ADAM17, PDI and β-actin.
siRNA studies
For knockdown of each target gene, four different siRNA oligonucleotides were tested by Western blotting, two of which were used for the actual experiments. For the experiments with MCF7 cells, a pool of the four siRNA oligonucleotides was used (cat. no. J-003453 5-8). ADAM10 (cat. no. D-004503 1 and 3) and ADAM17 (cat. no. J-003453 7 and 8) siRNA crossreactivity was also tested. Non-targeting siRNA (cat. no. D-001819), with minimal targeting of known genes, was used as a control. ADAM10, ADAM17, PDI (cat. no. J-01829) and nontargeting siRNA were added to cell monolayers and removed after 6 h. After 72 h cells were stimulated with 100 ng/ml PMA for 30 min at 37
• C. The medium was collected, spun down (25 000 g for 5 min) and assayed for AP.
Production of human anti-ADAM17 scFv (single-chain variable fragment) antibodies
Recombinant human ADAM17 ectodomain (TACE651) was biotinylated at an approx. 1:1 molar ratio using N-succinimidyl biotin (Invitrogen), checked for wild-type activity in a quenched fluorescent peptide cleavage assay and exposed to the scFv phage-display library [32] . Following two rounds of solutionphase selection, the eluted polyclonal scFv population was cloned into pSANG10-3F [33] and transformed into Escherichia coli BL21(DE3) cells (Stratagene). Individual scFv clones (384) were isolated from E. coli periplasm and ELISA-screened against immobilized recombinant ADAM17 (see below). Comprehensive screening details have been outlined previously [32] . ScFvs A7, A9, D3 and the negative control antibody B9, were further expressed in 500 ml of auto-induction shake flask cultures [33, 34] and purified by FPLC nickel-mediated immobilized metal-affinity chromatography.
ELISA characterization of human anti-ADAM17 scFv antibodies
For all standard ELISAs, 50 μl/well of 100 nM antigen (diluted in 50 mM Tris/HCl, pH 7.4, containing 10 mM CaCl 2 ) was coated on to a 96-well Maxisorp plate (Nunc) and incubated overnight at 4
• C. The following day, excess antigen was removed by three washes of 200 μl of PBS and each well was blocked with 200 μl of 5% (w/v) low-fat milk powder/PBS for 1 h at room temperature. Antibody [50 μl diluted in 3 % (w/v) lowfat milk powder/PBS] was added to each well and incubated for 1 h at room temperature. An anti-ADAM17 polyclonal IgY and an anti-ADAM10 rabbit polyclonal [diluted 1:2000 in 3 % (w/v) low-fat milk powder /PBS] were used as positive controls when necessary. Unbound primary antibody was removed by three washes with 200 μl of PBS containing 0.1 % Tween 20, followed by three washes with 200 μl of PBS. ScFv binding was detected using 50 μl/well of anti-FLAG-HRP antibody (Sigma-Aldrich, cat. no. A8592), N-TIMP-3-His 6 was detected using anti-His 6 -HRP antibody (R&D Systems, cat. no. MAB050H) and IgY was detected using goat anti-(chicken Ig-HRP) antibody (Abcam, cat. no. Ab6877); all antibodies were diluted 1:1000 in PBS with 3 % (w/v) low-fat milk powder. Following a further incubation/wash cycle, KPL (3,3 ,5,5 -tetramethylbenzidine) was added to each well and a chromogenic signal was allowed to develop. The reaction was stopped with 50 μl of 1M H 2 SO 4 and absorbance was measured at 450 nm using a Tecan Infinite-200. To determine basic affinity data, scFv titration ELISAs were performed against 100 nM immobilized ADAM17 ectodomain. K d values were determined from non-linear regression curve fitting (with a one site model for specific binding) in GraphPad Prism. To establish epitope proximity, each scFv (100 nM) was ELISA-screened against 100 nM recombinant ADAM17 ectodomain (Arg 215 -Arg 651 ), 100 nM ADAM17 catalytic domain (Arg 215 -Val 477 ) and 100 nM ADAM10 ectodomain (Thr 214 -Glu 672 ) (R&D Systems). The disulfide dependence of each scFv epitope was determined by comparing the ELISA-binding levels of each scFv with that of 100 nM reduced ADAM17 ectodomain (pre-treated with 100 μM DTT prior to coating). The scFv B9 was randomly selected from the naïve V-gene library and used as a negative control in all scFv ELISAs.
PDI-treated ADAM17 ELISA
Purified PDI (30 μM) was incubated in the presence of 10-fold molar excess DTT (300 μM) for 15 min at room temperature. Excess DTT was removed by passing the reduced PDI through two desalting columns (Pierce). Reduced PDI was subsequently split into two populations: one was stored on ice for 30 min (reduced PDI) and another incubated with iodoacetamide (300 μM) at room temperature for 30 min (alkylated PDI). Reduced and alkylated PDI preparations (30 μM) were independently added to 10 μM biotinylated recombinant human ADAM17 and incubated at 37
• C for 2 h. In addition, 10 μM ADAM17 was also incubated with 100 μM DTT or in buffer alone to provide reduced and non-reduced ADAM17 controls respectively. All reactions were performed in the presence of 50 mM Tris/HCl, pH 7.0, containing 10 mM CaCl 2 . Each ADAM17 solution was then diluted to 50 nM and aliquoted (50 μl per well) on to an ELISA plate pre-coated with 50 μl of 200 nM streptavidin. After a 20 min incubation, each well was washed six times with 200 μl of PBS containing 0.1 % Tween 20 to remove non-biotinylated PDI. Immobilized biotinylated ADAM17 was subsequently probed with 50 μl of 100 nM scFvs, 200 nM N-TIMP-3-His 6 , 10 nM ADAM17 polyclonal IgY antibody or 100 nM anti-PDI (RL-77) antibody, all diluted in PBS with 3 % (w/v) low-fat dried milk powder. Following a 1 h incubation at room temperature, each well was washed three times with 200 μl of PBS containing 0.1 % Tween 20 and three times with 200 μl of PBS. Subsequent immunoreactivity was detected as detailed above.
Fluorimetric ADAM17 activity assay
Recombinant ADAM17 (0.8 μM) was incubated in 50 mM Tris/HCl, pH 7.4, containing 10 mM CaCl 2 , either with or without a 3-fold molar excess of untreated bovine PDI at room temperature for the times stated. Aliquots (10 μl) were removed and assayed for ADAM17 activity against the fluorogenic substrate (7-methoxycoumarin-4-yl)-acetyl-Lys-Pro-Leu-GlyPro-Leu-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl-AlaArg-NH 2 [2 mM in FAB buffer (50 mM Tris/HCl, pH 7.4, containing 10 mM CaCl 2 , 0.05% Brij35 and 1 % DMSO)]. Reactions were run for 1000 s in an LS50B spectrophotometer with a total volume of 2 ml, with excitation at 320 nm and emission at 405 nm. Activities were expressed as a percentage of the untreated control.
Protein substrate assay
Recombinant ADAM17 (100 nM) was treated with increasing amounts of reduced PDI (0-800 nM) or with reduced and alkylated PDI (800 nM) in FAB buffer for 2 h at 37
• C. Subsequently, 5 μM GST-pro-TNFα was added to samples and was
Figure 1 ADAM17 mediates PMA-stimulated HB-EGF shedding in HeLa cells
(A) ADAM17 siRNA, but not ADAM10 siRNA, inhibits PMA-stimulated HB-EGF shedding. At 72 h after addition of siRNA, cells were stimulated with 100 ng/ml PMA for 60 min. Cell medium was collected and analysed for AP activity. (B) Verification of ADAM10 and ADAM17 protein knockdown. At 72 h after addition of ADAM10, ADAM17 or non-targeting (NT) siRNA, HeLa cells were lysed. Cell lysates were subjected to SDS/PAGE, transferred on to nitrocellulose membranes and probed with the relevant antibody (left-hand panel). siRNAs were also tested for ADAM10 and ADAM17 cross-reactivity (right-hand panel). The molecular masses in kDa are indicated on the right. incubated for 2 h at 37
• C. Each variable was resolved by SDS/PAGE (reducing 12 % gels) and stained with Coomassie Brilliant Blue.
Statistical analysis
All statistical analyses were performed using GraphPad Prism. Where possible, experiments were performed in biological triplicates and were repeated at least twice. Error bars in all figures refer to S.E.M.
RESULTS
Redox status modulates PMA stimulation of ADAM17 activity in a cell model of HB-EGF shedding
Using HeLa cells stably transfected with pro-HB-EGF fused to an AP reporter, HB-EGF-AP, we confirmed previous results [35] that it was rapidly 'shed' when the cells were stimulated with PMA (Supplementary Figure S1A available at http://www. BiochemJ.org/bj/428/bj4280439add.htm). Stimulated shedding activity was abrogated completely by treatment with TIMP-3 or with low-molecular-mass inhibitors of metalloproteinases (Supplementary Figure S1B) . Transient transfection with siRNAs targeting ADAM17, which ablated its expression by up to 90 %, inhibited PMA-stimulated shedding activity by up to 70 % (Figure 1 ), indicating that ADAM17 is the major sheddase. Endogenous shedding of HB-EGF-AP in unstimulated cells was low and was unaffected by ADAM17 siRNA treatment ( Figure 1A ). Specific ADAM10 siRNAs, which reduced ADAM10 protein levels by more than 75 %, had no effect on PMA-induced shedding activity ( Figure 1 ). As described recently by Wang et al. [24] , the treatment of cells with the reducing agents DTT or TCEP [tris(2-carboxyethyl)phosphine] was inhibitory to PMA-stimulated cellular ADAM17 shedding of L-selectin and we observed similar effects with HB-EGF-AP as the substrate (Figures 2A and 2B) .
It has been shown that PMA treatment of cells causes the generation of ROS [36] and that oxidizing agents, such as H 2 O 2 , can cause HB-EGF shedding by cells [37] and can activate ADAM17 [24] . Although exogenous H 2 O 2 was also mildly stimulatory to HB-EGF-AP shedding in our model (results not shown), we found that the effect of PMA on ADAM17 activity in HeLa cells was not inhibited by the presence of the antioxidant catalase (results not shown). However, the presence of the general free radical scavenger NAC, or the mitochondrial electron transport chain inhibitor MitoQ was inhibitory ( Figures 2C and  2D ), implicating mitochondrial ROS in the PMA action on ADAM17 in HeLa cells.
Thiol isomerases modulate HB-EGF shedding
Mature ADAM17 is thought to have 16 disulfide bonds [38] . As there is considerable potential for isomerization, notably of the two CxxC isomerase-like motifs in the disintegrin-cysteinerich domain that appear to be essential for ADAM17 activity [24, 39] , we postulated that these might be susceptible to changes in the cellular redox environment. Thiol isomerases, such as PDI and thioredoxin, which are sensitive to redox changes, have been implicated in the regulation of the thiol-and disulfidebond status and activity of various cell-surface proteins [17] . We therefore investigated their potential role in the modulation of ADAM17 activity. We found that the general thiol isomerase inhibitor bacitracin was indeed an efficient activator of HB-EGF-AP shedding, almost doubling its release in the presence of PMA, although it had little effect on constitutive shedding ( Figure 3A) . We confirmed that HB-EGF-AP shedding was still due to ADAM17 using specific siRNA ablation ( Figure 3B ). We hypothesized that certain disulfide isomers of ADAM17 could be less active than others and that an inactive form might be maintained by cellular thiol isomerase(s) activity. In support of this concept, an inhibitory antibody against PDI was found to enhance PMA shedding by approx. 60 % (Figures 3A and  3B ). This suggests that PDI could be a specific contributor to the thiol isomerase activities that are responsible for the downregulation of ADAM17 activity. Equally, addition of exogenous PDI to cells was moderately inhibitory (approx. 30 %) to PMAstimulated shedding, with no significant effect on endogenous shedding ( Figure 3C ), suggesting that endogenous PDI levels are largely sufficient to maintain ADAM17 in a low-activity form, or that (reduced) exogenous PDI is rapidly down-regulated by the Alkylated PDI has no effect on ADAM17 activity. After incubation with 500 nM exogenous reduced, or reduced and alkylated PDI for 10 min, cells were stimulated with 100 ng/ml PMA for 30 min. Cell medium was analysed for AP activity. (E) PDI knockdown increases PMA-stimulated ADAM17 activity. At 72 h after addition of siRNA, cells were stimulated with 100 ng/ml PMA for 30 min. Cell medium was analysed for AP activity. (F) Verification of the decrease of PDI protein expression after addition of PDI siRNA to HeLa cells relative to a control, non-targeting (NT) siRNA. At 72 h after addition of siRNA, cells were lysed, cell lysates were subjected to SDS/PAGE, transferred on to membrane and probed with a anti-PDI antibody.
PMA-induced oxidative environment in the experiment. When the thiol groups of exogenous PDI are blocked by reduction and alkylation, the inhibitory effect on ADAM17 activity is abrogated ( Figure 3D ). This indicates that PDI thiol groups are necessary for the regulation of ADAM17 sheddase activity. Reduction of total cellular PDI levels by transfection with siRNAs targeting PDI (to give an approx. 80 % depletion of protein levels; Figure 3F ) enhanced the effect of PMA-stimulated shedding by approx. 2-fold ( Figure 3E ). As for bacitracin or anti-PDI antibody treatment, this mode of PDI inhibition had no significant effect on constitutive cellular shedding of HB-EGF-AP. Another potential thiol isomerase, reduced thioredoxin, was a rather weak inhibitor of PMA-stimulated ADAM17 activity, but was not very stable in its reduced form (results not shown).
In summary, ablation of PDI activity (by antibody or siRNA) enhanced the action of PMA-stimulated pathways in HeLa cells. Comparable results were obtained using MCF7 cells (Supplementary Figures S2 and S3 available at http://www. BiochemJ.org/bj/428/bj4280439add.htm). We conclude that PMA might act in part via a PDI-mediated thiol isomerase mechanism that involves the modification of PDI redox activity.
ScFv antibodies and TIMP-3 detect PDI modulation of recombinant ADAM17
Using a recombinant form of the full ectodomain of human ADAM17 we have isolated scFv antibodies from a V-gene phagedisplay library [32] . Using an ELISA assay with either full-length ADAM17 ectodomain or the catalytic domain alone, we identified an antibody that exhibited specificity for the catalytic domain of ADAM17 (A9; K d of 30 nM) and two antibody clones that required the presence of the non-catalytic regions (disintegrincysteine-rich domain) (A7, K d of 90 nM; D3, K d of 20 nM) ( Figures 4A and 4B) . A randomly selected control scFv B9 failed to bind to all the tested antigens ( Figure 4A ) and was used as a negative control in all subsequent ELISAs (results not shown). None of the antibodies bound to recombinant ADAM10 ( Figure 4B ). The 16 potential disulfide bonds in the ectodomain of ADAM17 are thought to be key elements in the determination of its tertiary structure [40] . As all scFvs were selected against non-reduced ADAM17 (with no detectable free thiols), disulfidedependent antigen topology could result in scFvs harbouring disulfide-dependent epitopes. To explore this idea, the binding were ELISA-probed with each scFv to obtain basic epitope and specificity information. ScFv A9 bound directly to the ADAM17 catalytic domain, whereas scFvs A7 and D3 did not. None of the scFvs cross-react with ADAM10. (C) ScFvs A7 and A9 have disulfide-dependent epitopes. Pre-treatment of ADAM17 ectodomain with 100 μM DTT abolished the immunoreactivity of scFvs A7 and A9, whereas the binding of scFv D3 and a polyclonal IgY antibody remained unaltered. This suggested A7 and A9 recognized disulfide-dependent epitopes. (D) PDI modifies ADAM17 non-catalytic regions. Biotinylated recombinant human ADAM17 ectodomain (10 μM) was incubated with either 100 μM DTT, 30 μM reduced PDI or 30 μM alkylated PDI. ADAM17 was subsequently immobilized on a streptavidin-coated ELISA plate and excess PDI was removed by multiple washes. The topological status of the ADAM17 catalytic domain was then probed using scFvs A9 (catalytic epitope), A7 and D3 [non-catalytic (Non-Cat) epitope] and an anti-ADAM17 polyclonal IgY antibody. Although the ADAM17 catalytic domain is a disulfide-dependent structure (A9 scFv binding was lost after direct reduction), PDI treatment of the ectodomain did not alter the epitope selectivity of scFv A9. In contrast, the ADAM17 non-catalytic epitopes recognized by A7 and D3 were abolished by treatment with reduced PDI. Inactive alkylated PDI did not disrupt any antibody binding. (E) PDI modification of ADAM17 ectodomain blocks N-TIMP-3 binding. The ADAM17 ectodomain was treated as described in (D) and probed with N-TIMP-3. Despite the apparent structural integrity of the catalytic domain following PDI treatment (A9 binding was unaltered), PDI modification of ADAM17 dramatically obstructed N-TIMP-3 binding.
of each scFv to reduced ADAM17 was investigated. Treatment of ADAM17 with DTT strongly reduced immunoreactivity with A7 and A9 ( Figure 4C ), indicating that they do indeed recognise complex three-dimensional disulfide-dependent epitopes. In contrast, DTT treatment had no effect on ADAM17 binding to D3, suggesting a simple linear epitope ( Figure 4C ). ScFvs A7, A9 and D3 were subsequently used to monitor PDI modulation of the recombinant ADAM17 ectodomain. Treatment of ADAM17 with reduced PDI substantially abrogated ADAM17 recognition by the A7 and D3 non-catalytic epitopes, but not by the A9 catalytic epitopes ( Figure 4D ; Table 1 ). Similar results were obtained with untreated PDI, suggesting the purified enzyme exists in a reduced active state (results not shown). PDI that had been previously inactivated by reduction and alkylation had no effect on ADAM17 immunoreactivity against D3, A7 or A9 indicating the reduced thiols of PDI were essential for ADAM17 modulation. All forms of ADAM17 used in the assays were equally well-recognized by a polyclonal antibody IgY against ADAM17 ( Figure 4C ). The possibility that non-specific binding of PDI could be responsible for changes in scFv binding were ruled out as an antibody against PDI (RL-77) showed that no PDI remained in the assays after the wash protocol was employed (results not shown). Treatment of ADAM17 with reduced thioredoxin (at a concentration equivalent to that equimolar to the thioredoxin motifs of PDI) caused a small decrease in A7 and D3 immunoreactivity towards ADAM17, but was not as effective as PDI (results not shown). Interestingly, PDI treatment of the ADAM17 ectodomain reduced its ability to bind the N-TIMP-3 ( Figure 4E ). However, PDI treatment of ADAM17 did not disrupt the disulfide-dependent catalytic domain epitope of scFv A9, suggesting that the ADAM17 catalytic domain remained unaltered.
In summary, our results indicate that PDI treatment of ADAM17 modifies the epitopes recognized by scFvs A7 and D3, presumably by a structural change in the non-catalytic ADAM17 disintegrincysteine-rich domain. Moreover, PDI treatment also modifies the accessibility of N-TIMP-3 to the ADAM17 catalytic site, while retaining the disulfide-dependent catalytic domain epitope for scFv A9. Finally, recombinant ADAM17 cleavage of a quenchedfluorescent peptide substrate ( Figure 5A ) or of macromolecular substrates, GST-pro-TNFα ( Figure 5B ) and myelin basic protein (results not shown), could be inhibited by pre-treatment with PDI, but not with alkylated PDI. Together, these results suggest that PDI acts by isomerizing the disulfide bonds in the noncatalytic domains of ADAM17, causing a conformational shift in Figure 4(D) . +, immunoreactivity with antibody as determined by ELISA; −, no immunoreactivity with antibody as determined by ELISA.
Catalytic domain
Non the enzyme structure and obstruction of access to the ADAM17 catalytic site.
PMA modulates the thiol status of PDI but not ADAM17
We also investigated whether PMA had any effects on PDI and ADAM17 interactions at the cell surface. Although PDI is largely associated with the endoplasmic reticulum we were able to detect PDI expression at the HeLa cell surface by immunofluorescence (results not shown), which has been described previously for a number of different cells [41] . Biotinylation of cell-surface proteins with sulfo-NHS-biotin, a reagent reactive with free amino groups, was used to verify by immunoblotting the presence of both mature ADAM17 and PDI at the surface of HeLa cells before and after a brief PMA treatment. The level of total cell-surface ADAM17 and PDI did not change significantly after 30 min of exposure to PMA (Figures 6A  and 6B ). Total cellular levels of HB-EGF were not modified by PMA exposure, but levels at the cell surface decreased, as might be expected (Supplementary Figure S4 available at http://www.BiochemJ.org/bj/428/bj4280439add.htm). The lack of actin biotinylation during cell-surface labelling confirmed that biotinylation of intracellular proteins had not occurred. In studies of ADAM17 trafficking in the pre-monocytic cell line THP-1, a similar biotinylation study by Black and colleagues showed that cell-surface ADAM17 levels had started to decrease after 30 min of PMA treatment [3] . Levels of ADAM17 were somewhat lower in HeLa cells and turnover at the cell membrane appeared to be slower in the present study. However, after PMA treatment for 1 h we also began to observe the disappearance of surface ADAM17 (results not shown). Labelling with a cellimpermeable thiol-biotinylating reagent MPB showed that cell-surface ADAM17 had some free thiol reactivity and that this did not change significantly in the presence of PMA ( Figures 6A  and 6B ). In contrast, the free thiol content of PDI fell by approx. 40 % relative to unstimulated cells, suggesting that it was more oxidized after PMA exposure and potentially less active. When cells were treated with PMA in the presence of the ROS scavenger NAC the total level of cell-surface PDI protein (i.e. sulfo-NHSbiotin-labelled) fell, but the level of free thiols associated with the extracellular PDI (MBP-labelled) was restored to that of non-PMA-stimulated cells ( Figure 6C ). We conclude that PMA generated ROS have modulated the level of active reduced PDI at the cell surface, with consequent effects on the active isomer of ADAM17.
We were unable to detect PDI functional activity at the surface of HeLa cells due to the poor sensitivity of the available assays. The level of reduced PDI detectable by MBP was therefore used as a surrogate assay for PDI activity as an ADAM17 isomerase. The functional association between ADAM17 and PDI was biochemically analysed. Initial failure to co-immunoprecipitate the proteins from lysates of surface-biotinylated HeLa cells showed that ADAM17 and PDI do not form stable complexes. This was confirmed by surface plasmon resonance studies of binding between isolated PDI and ADAM17, which showed that only extremely transitory complexes formed (results not shown). However, PDI co-immunoprecipitated with ADAM17 when cells were treated with trichloroacetic acid, implying that trapping of transient mixed disulfide intermediate complexes can occur, as described by Kaiser et al. [31] . After PMA treatment there was no detectable change in this binding ( Figure 6D ). No evidence for the association of the thiol isomerases ERp5 and thioredoxin, or the substrate HB-EGF-AP with ADAM17 could be detected by immunoblotting (results not shown).
In contrast with the cellular enzyme, the recombinant ADAM17 ectodomain was found to have no free thiol activity and did not bind the thiol reagent MPB (Supplementary Figure S5 available at http://www.BiochemJ.org/bj/428/bj4280439add.htm). Purified PDI had extensive levels of free thiols that were lost after treatment with H 2 O 2 or the alkylating agent iodoacetamide. Incubation of recombinant ADAM17 with PDI caused no change in the free thiol status of either protein (Supplementary Figure S5) . We conclude that any effect of PDI on ADAM17 is due to its isomerase activity The effect of NAC on total and free thiol levels of cell-surface PDI. Cells were exposed to 1 mM NAC for 15 min, then to 100 ng/ml PMA with NAC for 30 min at 37 • C as indicated. Subsequently, amine groups were biotinylated for 45 min at 4 • C. Streptavidin immunoprecipitation was performed, samples were subjected to SDS/PAGE and Western blotting and probed with a PDI antibody (RL77). Molecular masses are indicated on the right-hand side. (D) PDI transiently interacts with ADAM17 at the HeLa cell surface. After exposure to 100 ng/ml PMA for 30 min, HeLa cells were surface biotinylated (amine groups). For stabilization of disulfide bonds, cells were then incubated in 10 % (v/v) trichloroacetic acid in PBS for 30 min, before pH was adjusted to 7.0 with Tris/OH (pH 9.5). Cells were lysed and ADAM17 immunoprecipitation (IP) was performed. After releasing the immunocomplex from the beads, a secondary immunoprecipitation was performed for streptavidin. Samples were subjected to SDS/PAGE and Western blotting, after which membranes were probed with specific antibodies, as indicated. Molecular masses are indicated on the right-hand side.
rather than as a reducing agent. PMA modulation of cellular ADAM17 activity is down-regulated by counteracting surface PDI activity. Removal of PDI by an inhibitory antibody or siRNA treatment of cells thus gives a marked enhancement of ADAM17.
DISCUSSION
The rapid activation of ADAM17 to cause cleavage and 'shedding' of cell-associated factors such as TNFα and EGFR ligands has long been known to be efficiently effected by the activation of protein kinase C by the phorbol ester PMA, or by inhibition of protein tyrosine phosphatases [1] . Although spatial regulation of ADAM17 and its substrates within the plasma membrane may control shedding events it has proved difficult to unequivocally substantiate this concept. PMA has been shown to ultimately decrease the levels of ADAM17 at the surface of monocytic cells, although lipopolysaccharide stimulation had no effect and no change in localization could be seen [3] . PMA has also been shown to enhance short-term activity of ADAM17 against a peptide substrate [42] . Roles for ROS, generated by plasma membrane NADPH oxidases or by mitochondria, downstream of phorbol ester stimulation of protein kinase C, have been proposed previously as mediators of shedding activities [5] [6] [7] . The cellular modulation of substrate availability in response to stimuli, such as ROS generation, is known to be a significant factor in the determination of rates of release of membrane-bound growth factors [1, 12, 13] . Pro-HB-EGF has been shown to be exported from the nucleus of bladder cancer cells in response to increases in ROS and recruited to a lipid-raft fraction where cleavage occurred. These trafficking events were key to the proteolytic release of soluble HB-EGF [12] .
ROS have been invoked in many of the cellular stress responses that up-regulate ADAM17 shedding activity. Wang et al. [24] found that neutrophil ADAM17 could be mildly activated by H 2 O 2 and proposed that reduction-oxidation modifications of cysteine sulfydryl groups in ADAM17 may be regulating its Lselectin shedding activity at the cell surface. As we had similar results using H 2 O 2 as a stimulant, we proposed to focus on the potential mechanisms of redox modulation of ADAM17 itself. We showed that exposure of HeLa cells to inhibitors of PDI, including the metallo-antibiotic bacitracin, which inhibits enzyme catalysed disulfide exchange, antibodies against PDI or siRNAs ablating PDI, could indeed up-regulate PMA-stimulated ADAM17-mediated shedding of HB-EGF-AP. These results led us to propose that PDI, and possibly other thiol isomerases, could modulate ADAM17 function, as has been shown for other disulfide-bonded cell-surface proteins, such as some integrins Figure 7 Model of PDI isomerization of the ADAM17 ectodomain ADAM17 homology models permit multiple ectodomain conformations [47] . In vitro results suggest PDI-mediated thiol isomerization of the ADAM17 non-catalytic domains (blue) disrupt accessibility to its catalytic domain (red) ('Closed' ADAM17). PDI antagonists consent reversal of this process, with subsequent re-accessibility of the catalytic zinc (grey) ('Open' ADAM17). The mechanism of reversal requires further investigation. [17] . We obtained similar results with other cell types, e.g. Figures S2 and S3 ), suggesting that this could be a general regulatory mechanism. Biotinlabelling studies using the thiol-reactive agent MBP showed that short-term treatment of cells with PMA reduces the free thiol level of extracellular PDI by over 40 %, but had no effect on ADAM17. A low level of free thiols was detected on cellular ADAM17 suggesting that a degree of flux between free thiol groups and disulfide bonds may be occurring, but we could not detect a significant difference before and after PMA treatment of cells. We concluded that PDI could be acting as an isomerase of ADAM17, modulating the disulfide bond patterning, but not the overall ratio of free sulfydryl groups to disulfides, with the effect of maintaining an inactive isomer of ADAM17. This concept was supported by our studies with the recombinant ADAM17 ectodomain, in which PDI treatment caused conformation changes, as reported by conformationspecific antibodies, without any changes in free thiol status. This also led to a decrease in the ability of ADAM17 to cleave both a small fluorescent peptide substrate and larger protein substrates, as well as to bind to N-TIMP-3 in an ELISA-style assay. The N-TIMP-3 results concur with our previous observations that the disintegrin-cysteine-rich domain of ADAM17 interferes with binding and inhibition of the catalytic domain [43, 44] . PDI had no effect on the activity of the ADAM17 metalloproteinase domain alone (results not shown). The disulfide bond patterning of ADAM17 could determine its conformation, and PDI modulation of that pattern would hence modify the shape and function of the enzyme. Mutation of Cys 600 in ADAM17 has been shown to lead to a loss of activity when the mutant was expressed in transfected cells, implying it is important for enzyme function [39] . However, endoplasmic reticulum folding problems occur in many mutants where cysteine residues are replaced in ADAM17 (N. Taylor and G. Murphy, unpublished observations), which means that the results are harder to interpret, as there may never be a secreted form. Studies of the crystallographic structure of related snake venom adamalysins have suggested that there could be at least two radically different 'C' and 'I' conformations of the enzymes that reflect different disulfide-bonding patterns of the disintegrin-like domain (Figure 7 ) [45] . Hence ADAM17 could adopt similarly 'closed' and 'open' conformations in which the disintegrin-cysteine-rich domain modify accessibility of substrates to the metalloproteinase active-site cleft.
MCF7 cells (Supplementary
The question of how PMA treatment of cells regulates PDI may be partly explained by the modulation of the redox environment through ROS generation, hence reducing the level of free thiol groups. It is still not clear why the presence of PMA facilitates the effective inhibition of PDI to allow further activation of ADAM17 when PDI inhibition of resting cells has no effect. One possibility is that PDI and ADAM17, or ADAM17 and its substrate HB-EGF, are brought into proximity to each other in a specific membrane compartment at, or near, the cell surface. However, we have not been able to demonstrate differences in their cell-surface localization in the presence or absence of PMA. As shown in Figure 6 (D) we found little difference in the amount of extracellular PDI-ADAM17 complex with and without PMA stimulation. It is known that PMA regulates the dynamics of the early endosome compartment of cells [46] , hence future studies will focus on the role of the plasma membrane for the PMAmediated effects on the extracellular function of PDI.
Thiol isomerase activity of PDI is thought to be largely confined to the endoplasmic reticulum during protein folding, although isomerization of thrombospondin-1 extracellularly has been described [41] . The ability of rapid changes of redox status at the cell surface to modulate the behaviour of proteins has long been appreciated. In the case of integrins the effect of PDI on conformation and activity has been monitored in a similar fashion using conformation-specific antibodies and interactions with ligands [18] . It is significant that this mode of regulation can be extended to membrane proteases, such as ADAM17 and possibly to other members of the ADAM and ADAM-TS (ADAMs with thrombospondin motifs) families that have numerous disulfide bonds and apparently rapid activation mechanisms, and poses the question of the importance of redox and thiol isomerases in the regulation of the pericellular environment. The role of ROS generation in response to many cellular stimuli, including stress responses, in the modulation of the redox environment both intraand extra-cellularly is thought to be instrumental in the regulation of many signalling pathways. Effects on thiol isomerases could be key to such regulation, with ADAM17 among the targets. 5) and alkylated PDI (lanes 4 and 6) were incubated alone (lanes 3 and 5) or with ADAM17 (lanes 5 and 6) at 37 • C for 2 h. The subsequent thiol status of each mixture was investigated by MPB labelling (the molar ratio ADAM17/MPB was 1:10) for 2 h at room temperature. Samples were resolved by SDS/PAGE, transferred on to a nitrocellulose membrane and subjected to Western blotting (W.B.) for extra-avidin-HRP. The molecular masses are indicated on the left.
